Innovus Pharmaceuticals Announces Receipt of Notice of Intention to Grant Sensum+® European Patent

The Patent to Extend Innovus Pharma’s Protection for its
Innovative Product in Europe

SAN DIEGO–(BUSINESS WIRE)–Innovus Pharmaceuticals, Inc. (“Innovus Pharma”) (OTCQB Venture Market:
INNV), today announced that it has received a Notice of Intention to
Grant from the European Patent Office (“EPO”) to issue a European-wide
patent entitled “Sensitization composition and method of use” for
its Sensum+® product, for reduced penile sensitivity. On March 8, 2017,
Innovus Pharma announced that it received the CPNP notification number
required for commercialization of Sensum+® in all 28 member countries of
the European Union.

“Receipt of the Notice of Intention to Grant from the EPO adds great
value to the CPNP notification we received earlier in the month to
market Sensum+® in Europe and is a testament to the innovation of our
products and our continued ability to obtain patents that protect one of
our best-selling products,” said Dr. Bassam Damaj, President and Chief
Executive Officer of Innovus Pharma. “Having a patented product should
increase our ability to enter into new commercial partnerships for
Sensum+® in Europe.”

About Sensum+®

Sensum+® is a non-medicated cream which moisturizes the head and shaft
of the penis for enhanced feelings of sensation and greater sexual
satisfaction. It is a patent-pending blend of essential oils and
ingredients generally recognized as safe that recently commenced
marketing in the U.S. Innovus Pharma acquired the global ex-U.S.
distribution rights to Sensum+® from Centric Research Institute. The
safety and efficacy of Sensum+® was evaluated in two post-marketing
survey clinical studies in circumcised and non-circumcised men. A total
of 382 men used Sensum+® twice daily for 14 consecutive days followed by
once daily for eight weeks and as needed thereafter. Study participants
reported a ~50% increase in penile sensitivity with the use of Sensum+®.

About Innovus Pharmaceuticals, Inc.

Headquartered in San Diego, Innovus Pharma is an emerging
over-the-counter (“OTC”) consumer goods and specialty pharmaceutical
company engaged in the commercialization, licensing and development of
safe and effective non-prescription medicine and consumer care products
to improve men’s and women’s health and vitality and respiratory
diseases. Innovus Pharma delivers innovative and uniquely presented and
packaged health solutions through its (a) OTC medicines and consumer and
health products, which we market directly; (b) commercial partners to
primary care physicians, urologists, gynecologists and therapists; and
(c) directly to consumers through our on-line channels, retailers and
wholesalers. The Company is dedicated to being a leader in developing
and marketing new OTC and branded Abbreviated New Drug Application
(“ANDA”) products. The Company is actively pursuing opportunities where
existing prescription drugs have recently, or are expected to, change
from prescription (or Rx) to OTC.

Innovus Pharma’s Forward-Looking Safe Harbor:

Statements under the Private Securities Litigation Reform Act, as
amended: with the exception of the historical information contained in
this release, the matters described herein contain forward-looking
statements that involve risks and uncertainties that may individually or
mutually impact the matters herein described for a variety of reasons
that are outside the control of the Company, including, but not limited
to, the Company’s need for additional equity or debt financing, to
receive applicable regulatory approval for its products, successfully
commercialize Sensum+® in Europe and other products in other countries
and to achieve its other development, commercialization, financial and
staffing objectives. Readers are cautioned not to place undue reliance
on these forward-looking statements as actual results could differ
materially from the forward-looking statements contained herein. Readers
are urged to read the risk factors set forth in the Company’s most
recent annual report on Form 10-K, subsequent quarterly reports filed on
Form 10-Q and other filings made with the SEC. Copies of these reports
are available from the SEC’s website or without charge from the Company.

Contacts

Chesapeake Group
Kevin Holmes, 410-825-3930
info@chesapeakegp.com